OSI Pharmaceuticals said on Sunday that it had agreed to sell itself to Astellas Pharma of Japan for $4 billion in cash, after its suitor raised its takeover offer.
Under the terms of the deal, OSI shareholders will receive $57.50 a share, a 55 percent premium to OSI’s share price on Feb. 26, the last trading day before Astellas made its first takeover bid public. The new price is 10.5 percent higher than Astellas’ first proposal of $52 a share.
The sale ends a two-month standoff over OSI, a biotechnology company whose main product is Tarceva, a drug used to treat several kinds of cancer in conjunction with chemotherapy. Astellas initially unveiled a $3.5 billion unsolicited offer in March, which OSI rejected soon after.
After Astellas began a tender offer for OSI’s shares and proposed a rival slate of directors, however, the American drug maker agreed to open its books to its unsolicited suitor.
Analysts have said that they expected Astellas to prevail, though at a higher price than its initial offer.
Colin Goddard, OSI’s chief executive, said in a statement: “We believe today’s announcement recognizes the significant value we have built for our stockholders while providing the merged companies the opportunity to forge a stronger collective path forward in a shared mission to provide innovative new medicines to patients around the world.”
Founded in 1983 and based in Melville, N.Y., OSI’s main product is Tarceva, which generated $1.2 billion in sales last year. OSI has sought to expand Tarceva’s use in cancer treatment.
The company reported $75.9 million in net income last year, atop $428.1 million in revenue. It has 524 employees.
The deal marks a successful effort by Astellas to acquire an American biotech company, after losing a battle over CV Therapeutics last year to Gilead Sciences.
Astellas, based in Tokyo and one of Japan’s biggest drug makers, has made it clear that a major priority was expanding its oncology drug pipeline.
“The merger with OSI provides Astellas with a top-tier oncology platform in the U.S and an expanded product portfolio and pipelines,” Masafumi Nogimori, Astellas’s chief executive, said in a statement.
Astellas was advised by Citigroup and the law firm Morrison & Foerster. OSI was advised by Centerview Partners, Lazard and the law firm Skadden, Arps, Slate, Meagher & Flom.
Monday, May 17, 2010
Astellas to Buy OSI Pharmaceuticals for $4 Billion - DealBook Blog
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment